Influence of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development;Wpływ diety bogatotłuszczowej i podawania rozyglitazonu na profil lipidowy, insulinooporność i rozwój stłuszczenia wa̧troby

Polskie Archiwum Medycyny Wewnetrznej

Volumn 113, Issue 3, 2005, Pages 213-222

  Tacikowski, Tadeusz ^a,e   Nowicka, Grazyna ^b   Bujko, Jacek ^c   Walewska Zielecka, Bozena ^d   Dzieniszewski, Jan ^a  

^a Szpitalnego z Klinika Chorób Metabolicznych i Gastroenterologii   (Poland)

^b Instytutu Zywno ci i Zywienia   (Poland)

^c Zakładu Higieny ^*

^d Zak adu Higieny   (Poland)

^e Klinika Chorób Metabolicznych Gastroenterologii   (Poland)

Author keywords

High fat diet; Insulin resistance; NAFLD; Nonalcoholic liver steatosis; Rosiglitazone

Indexed keywords

C PEPTIDE; CARBOHYDRATE; FAT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; ROSIGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT;

EID: 20944431961     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Clark J.M., Brancati F.L., Diehl A.M.E.: Nonalcoholic fatty liver diseases; the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology, 2001, 120, A-65.
2. Angulo P.: Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221.
3. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., Sheppard B.L.: A pilot study of a thiazolidinedione, troglitazone in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 519.
4. Smith S.A., Lister C.A., Toseland C.D., Buckingham R.E.: Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes. Metab., 2000, 2, 363.
5. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28, 412.
6. Scheuer P.J., Lefkowitch J.H.: Liver Biopsy Interpretation. Laboratory Techniques. W.B. Saunders Company Ltd, London, 1994, 10.
7. MacSween R.N.M., Burt A.D., Portmann B.C., Ishak K.G., Scheuer P.J., Anthony P.P.: Pathology of the Liver. IV, Churchill Livingstone, Londyn, 2002.
8. Farrell G.C., Leclercq I., Horsmans Y.: Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease? Hepatology, 2002, 35, 731.
9. Zhang B.H., Weltman M., Farrell G.C.: Does steatohepatitis impair liver regeneration? A study in a dietary model of non-alcoholic steatohepatitis in rats. J. Gastroenterol. Hepatol., 1999, 14, 133.
10. Koteish A., Diehl A. M.: Animal models of steatosis. Semin. Liver Dis., 2001, 21, 89.
11. Gilat T., Leikin-Frenkel A., Goldiner I., Juhel C., Lafont H., Gobbi D., Konikoff F.M.: Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology, 2003, 38, 436.
12. Shavila J., King L.J., Parke D.V.: Spontaneous development of fatty liver in ferrets in a toxicology study. Toxicology. 1996, 16, 112, 105.
13. Del Moral M.L., Esteban F.J., Torres M.I. i wsp.: High-fat sunflower and olive oil diets affect serum lipid levels in steatotic rat liver differently. J. Nutr. Sci. Vitaminol (Tokyo), 1997, 43, 155.
14. Boden G.: Effects of Free Fatty Acids (FFA) on Glucose Metabolism: Significance for Insulin Resistance and Type 2 Diabetes. Exp. Clin. Endocrinol. Diabetes., 2003, 111, 121.
15. Boden G.: Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2002, 5, 545.
16. Kraegen E.W., Cooney G.J., Ye J.M., Thompson A.L., Furler S.M.: The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type 11 diabetes and obesity. Exp. Clin. Endocrinol. Diabetes, 2001, 109, 2, S189.
17. Bisschop P.H., de Metz J., Ackermans M.T. i wsp.: Dietary fat content alters insulin-mediated glucose metabolism in healthy men. Am. J. Clin. Nutr., 2001, 73, 554.
18. Atkins R.C.: Dr.Atkins' New Diet revolution. New edition. 2002.
19. Westman E.C., Yancy W.S., Edman J.S., Tomlin K.F., Perkins C.E.: Effect of 6-month adherence to a very low carbohydrate diet program. Am. J. Med., 2002, 113, 30.
20. Anderson J.W., Konz E.C., Jenkins D.J.: Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review. J. Am. Coll. Nutr., 2000, 19, 578.
21. Freedman M.R., King J., Kennedy E.: Popular diets: a scientific review. Obes. Res., 2001, 9 suppl. 1, 1S.
22. Ziemlański S.: Zapotrzebowanie człowieka na wȩglowodany [w:] Normy żywienia człowieka, (red.) S. Ziemlańskiego. PZWL. Warszawa, 2001, 53.
23. Kwiterovich P.O. Jr, Vining E.P., Pyzik P., Skolasky R. Jr, Freeman J.M.: Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA, 2003, 20, 290, 912.
24. Han D.H., Hansen P.A., Host H.H., Holloszy J.O.: Insulin resistance of muscle glucose transport in rats fed a high-fat diet: a reevaluation. Diabetes, 1997, 46, 1761.
25. Anderson J.W., Konz E.C., Jenkins D.J.: Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review. J. Am. Coll. Nutr., 2000, 19, 578.
26. Tacikowski T., Milewski B., Dzieniszewski J., Rakoczy A., Klosiewicz-Latoszek L.: Stłuszczenie wa̧troby oceniane badaniem ultrasonograficznym u osób z hiperlipoproteinemia̧. Wiadomości Lekarskie, 1994, 19-20, 726.
27. Tacikowski T., Dzieniszewski J., Rakoczy A., Tacikowska M.: Hipertriglicerydemia jako niezależny od otyłości czynnik ryzyka rozwoju stłuszczenia wa̧troby u osòb z hiperlipoproteinemia̧. Gastroenterologia Polska, 2001, 8, 143.
28. Axen K.V., Dikeakos A., Sclafani A.: High dietary fat promotes syndrome X in nonobese rats. Nutr. 2003, 133, 2244.
29. Storgaard H., Jensen C.B., Vaag A.A., Volund A., Madsbad S.: Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism, 2003, 52, 885.
30. Ebbeling C.B., Leidig M.M., Sinclair K.B., Hangen J.P., Ludwig D.S.: A reduced-glycemic load diet in the treatment of adolescent obesity. Arch. Pediatr. Adolesc. Med., 2003, 157, 773.
31. Westman E.C., Yancy W.S., Edman J.S., Tomlin K.F., Perkins C.E.: Effect of 6-month adherence to a very low carbohydrate diet program. Am. J. Med., 2002, 113, 30.
32. Sharman M.J., Kraemer W.J., Love D.M. i wsp.: A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J. Nutr., 2002, 132, 1879.
33. Storlien L.H., Higgins J.A., Thomas T.C. i wsp.: Diet composition and insulin action in animal models. Br. J. Nutr., 2000, 83 suppl. 1, S85.
34. Akiyama T., Tachibana I., Shirohara H., Watanabe N., Otsuki M.: High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat. Diabetes Res. Clin. Pract., 1996, 31, 27.
35. Christiansen E., Schnider S., Palmvig B., Tauber-Lassen E., Pedersen O.: Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects of postprandial insulinemia and glycemia in obese patients with NIDDM. Diabetes Care, 1997, 20, 881.
36. Lanza-Jacoby S., Phetteplace H., Tripp R.: Enteral feeding a structured lipid emulsion containing fish oil prevents the fatty liver of sepsis. Lipids., 1995, 30, 707.
37. Abbasi F., Brown B.W. Jr, Lamendola C., McLaughlin T., Reaven G.M.: Relationship between obesity, insulin resistance, and coronary heart disease risk. J. Am. Coll. Cardiol., 2002, 4, 40, 937.
38. Ferrannini E., Natali A., Bell P., Cavallo-Perin P., Lalic N., Mingrone G.: Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J. Clin. Invest., 1997, 100, 1166.
39. Kramer D., Shapiro R., Adler A., Bush E., Rondinone C.M.: Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001, 50, 1294.
40. Smith S.A., Lister C.A., Toseland C.D., Buckingham R.E.: Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes. Metab., 2000, 2, 363.
41. Kramer D., Shapiro R., Adler A., Bush E., Rondinone C.M.: Insulin- sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism, 2001, 50, 1294.
42. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., Sheppard B.L.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2001, 96, 519.
43. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Sponseller C.A., Hampton K., Bacon B.R.: Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. J. Hepatol., 2003, 38, 434.
44. Pagano G., Pacini G., Musso G. i wsp.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology, 2002, 35, 367.
45. Chitturi S., Abeygunasekera S., Farrell G.C. i wsp.: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35, 373.
46. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., Juarbe H.M.: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med., 1998, 129, 36.
47. Neuschwander-Tetri B.A., Isley W.L., Oki J.C. i wsp.: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern. Med., 1998, 129, 38.
48. Forman L.M., Simmons D.A., Diamond R.H.: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med., 2000, 18, 132, 118.
49. Al-Salman J., Arjomand H., Kemp D.G., Mittal M.: Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med., 2000, 132. 121.